|
Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Business Market Research
Energy Market Research
Financial Market Research
Pharmaceutical Market Research
Telecoms Market Research
|
Home > Market Research > Prescription Medicines > The Pharmaceutical Market: Denmark
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Denmark has a stable political system and a stable economy. However, it was hit hard by the global economic downturn, with GDP contracting by 5.1% in 2009, according to figures from the Economist Intelligence Unit. GDP growth is projected to rise gradually to 0.5% in 2010 and 2.0% by 2015. Meanwhile, healthcare expenditure has continued its steady growth in the past few years, increasing by 7.1% to reach DKK118.3 billion (US$21.7 billion) in 2007, with private expenditure accounting for around 16% of the total.
Although companies are free to set their own prices, products will only be reimbursed at the level of the lowest generic drug in each class unless it can be shown that there is a distinct therapeutic benefit. This has proved to be an effective way to drive pharmaceutical prices down.
Over 17,000 people are employed in the Danish pharmaceutical industry, including people employed in the production of raw materials, production of pharmaceuticals and wholesales. There is strong domestic production although many producers focus on Denmark’s export market, therefore many pharmaceutical imports are in retail-ready packages.
Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long-standing balance of trade surplus, which was in excess of US$4.7 billion in 2008. Between 2004 and 2008, imports increased by a CAGR of 11.9% to US$3.2 billion, while exports increased by a CAGR of 10.5% to US$7.9 billion.
Leo Pharma announced its acquisition of Australian dermatology specialist Peplin for US$287.5 million in September 2009. In the same month, the company announced it is to reacquire the licensing rights to its psoriasis portfolio, currently held by Warner Chilcott.
Lundbeck announced around 200 job cuts in Denmark in September 2009, in an effort to reduce costs. Other cost-saving measures that the company is implementing are insourcing and changing the travel behaviour of employees.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.
Top of Page
Table of Contents
EXECUTIVE SUMMARY 1
Introduction . 2
Pharmaceutical Market Analysis . 3
Size . 3
Market Structure . 4
Generics 8
OTCs . 8
Projections 9
Outlook 10
Imports 13
Domestic Production . 15
Trade Associations 15
Lægemiddel Industri Foreningen (LIF) . 15
Industriforeningen for Generiske Lægemidler (IGL) . 16
Domestic Producers 16
ALK-Abelló . 16
Genmab A/S 16
Leo Pharma . 17
Lundbeck A/S 17
Novo Nordisk . 18
PharmaDanica . 18
Pharmexa 18
Multinational Manufacturers 19
AstraZeneca Denmark . 19
GlaxoSmithKline (GSK) . 19
Nycomed . 19
Pfizer Denmark 19
Sandoz A/S (formerly Hexal A/S) . 20
Exports 20
Research & Development . 21
Pharmaceutical Regulatory Analysis 22
Pharmaceutical Regulation . 22
EU Drug Regulation 22
Centralised Procedure 22
EMEA 22
Generic Drugs . 22
National Procedures 23
DENMARK PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
ii Quarter I 2010
Marketing Authorisations . 23
Clinical Trials . 23
Authorised Pharmaceuticals . 24
Advertising 24
Intellectual Property 25
Supplementary Protection Certificates . 25
Data exclusivity 25
Pricing and Reimbursement 25
The Danish Medicines Agency . 25
Pricing . 26
Medicine Prices . 27
Price Index . 27
Reimbursement . 28
Executive Order . 29
Reimbursement System 30
Reference Price System 30
Generic Substitution 31
Pharmaceutical Distribution 32
Distributors 33
Amgros 33
Dupharma 33
K.V. Tjellesen A/S 33
Missionpharma 33
Nomeco A/S 33
Parallel Imports . 34
Conditions for a Parallel Import 34
Healthcare Analysis 35
Demographics . 35
Population . 35
Birth Rate . 36
Death Rate 36
Infant Mortality . 36
Life Expectancy at Birth . 36
Public Health . 37
Causes of Death 37
Incidence of Communicable Diseases/ Morbidity . 38
Cancer Incidence . 38
HIV/ AIDS 38
Healthcare System 39
PHARMA OUTLOOK DENMARK
Pharma Outlook espicom BUSINESS INTELLIGENCE
Quarter I 2010 iii
Health Expenditure . 41
Healthcare Infrastructure 43
Inpatient Analysis 44
Ambulatory Care . 46
Healthcare Personnel . 47
DIRECTORY 49
Healthcare Organisations 49
Distributors 49
Domestic Producers 49
Multinational Manufacturers 50
Methodology and Sources . 52
List of Tables
Key Data Projections, 2010-2015 . 2
Pharmaceutical Market, 2010 . 3
Pharmaceutical Market by Type, 2008 3
Number of Active Substances, Medicinal Products and Packs, 2004-2008 4
Sales of Medicinal Products at Retail Prices, 2004-2008 (DKK millions) . 5
Primary Healthcare Sector Pharmaceutical Sales by Therapeutic Group, Retail Prices, 2004-2008
(DKK millions) 5
Hospital Sector Pharmaceutical Sales by Therapeutic Group, Retail Prices, 2004-2008 (DKK
millions) 6
Pharmaceutical Consumption at Wholesale Prices, 2008 (DKK millions) . 6
25 Most Sold Human Specialities in Denmark at Wholesale Prices, 2005-2008 (DKK000s) . 7
Consumption of OTC medicines at Wholesale Prices, 2006-2008 (DKK 000s) . 8
Regional Comparison of Projected Pharmaceutical Markets, 2015 . 9
Projected Pharmaceutical Market, 2010-2015 10
Espicom Analysis of the Danish Pharmaceutical Market, 2010 11
SWOT Analysis of the Danish Pharmaceutical Market, 2010 12
Imports of Pharmaceuticals by Category, 2004-2008 (US$000s) 13
Import Trends, 2007-2008 (US$000s) 13
Leading Suppliers of Raw Materials, 2008 (US$000s) . 14
Leading Suppliers of Medicaments, 2008 (US$000s) 14
Domestic Pharmaceutical Manufacturing Turnover, 2003-2008 . 15
Exports of Pharmaceuticals, 2004-2008 (US$000s) . 20
Export Trends, 2007-2008 (US$000s) 20
Leading Destinations, 2008 (US$000s) . 21
DENMARK PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
iv Quarter I 2010
Pharmaceutical Research & Development Expenditure by LIF's Member Companies, 1997-06 . 21
Total Number of Pharmaceuticals, 2001-2006 24
Reimbursement Decisions 2001-2006 . 28
Number of Individual Reimbursement Applications, 2003-2008 . 29
Reimbursement Rates and Patient Charges, 2009 30
Pharmacies, 2001-2006 . 32
Summary of Demographic Indicators, 2008/2010 35
Regional Comparison of Projected Demographics, 2015 . 35
Projected Demographics, 2010-2015. 36
Causes of Death, 2005-2006 . 37
Healthcare Expenditure, 2010 41
Health Expenditure by Category, 2003-2007 (DKK millions) . 41
Regional Comparison of Projected Health Expenditure, 2015 42
Projected Health Expenditure, 2010-2015 . 43
Public Hospitals and Beds by Type, 2005 43
Hospital Beds by Specialty, 2005-2007 . 43
Hospital Activity, 2001-2006 . 44
Hospital Activity Summary by Specialty, 2005-2006 . 44
Number of Operations by Therapeutic Group, 2004 45
Outpatient Activity by Specialty, 2002-2004 . 46
Healthcare Personnel, 2002-2004 47
Staff Employed in the Hospital Sector, 2003-2005 . 47
Staff Employed in Municipal Healthcare, 2006-2008 48
Regional Comparison of Projected Physicians, 2015 . 48
Projected Physicians, 2010-2015 . 48
List of Figures
Regional Comparison of Projected Pharmaceutical Markets, 2015 . 9
Radar Graph of the Danish Pharmaceutical Market, 2010. 12
Central Government Expenditure on Health, 2000-2007 (DKK millions) 42
For full details, please email keithw@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
|
